Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates

   Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production
                       Approach for Vaccine Candidates

PR Newswire

SAN FRANCISCO, Jan. 3, 2013

SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Sutro Biopharma, a
biopharmaceutical company developing a new generation of protein therapeutics
utilizing Sutro's cell-free protein synthesis technology, today announced a
collaboration with Sanofi Pasteur -- the largest company entirely dedicated to
vaccines -- to produce two undisclosed vaccine candidates.

"This collaboration highlights the potential value of Sutro's biochemical
synthesis technology for the production of vaccines and provides additional
validation of the benefits of our technology platform," said William Newell,
chief executive officer of Sutro Biopharma. "We are looking forward to
expanding our expertise in protein expression into the field of vaccines with
an established leader in the area."

Details of the partnership were not disclosed. Four Oaks Partners advised
Sutro on the transaction.

About Sutro Biopharma

Sutro Biopharma, located in South San Francisco, has developed a cell-free
biochemical protein synthesis platform that enables the rapid design,
engineering, testing, and scalable production of novel proteins, including
those containing site-specific modifications and non-natural amino acids.
Sutro's platform allows the rapid and systematic exploration of many protein
variants to identify drug and vaccine candidates. Once product candidates are
identified, production can be rapidly and predictably scaled up to commercial
levels. Sutro has established a Good Manufacturing Practice (cGMP) facility
for the production of clinical supplies of materials using its biochemical
protein synthesis platform. Using this platform, Sutro is collaborating with
pharmaceutical and biotech companies to discover and develop novel vaccines,
peptide-based therapeutics, antibody drug conjugates, and bifunctional
antibodies to meet unmet medical needs. These products will significantly
extend the clinical impact of current approaches and are beyond what can be
envisioned with current cell-based expression technologies. For more
information, visit

Media Contacts:

David Schull or Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4271
(212) 845-4292
(347) 591-8785 (mobile)

SOURCE Sutro Biopharma

Press spacebar to pause and continue. Press esc to stop.